TNK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tae-684 (SCHEMBL282775)	1.00	2/20
Tofacitinib (SCHEMBL322753)	1.00	2/20
SCHEMBL352344	0.57	2/20
SCHEMBL352332	0.56	2/20
SCHEMBL351447	0.56	2/20
SCHEMBL168388	0.55	2/20
SCHEMBL350642	0.54	2/20
SCHEMBL352297	0.54	2/20
SCHEMBL352328	0.54	2/20
SCHEMBL191238	0.54	2/20
SCHEMBL351884	0.53	2/20
SCHEMBL351883	0.50	2/20
SCHEMBL352300	0.49	2/20
SCHEMBL20079	0.49	2/20
SCHEMBL352529	0.48	2/20
Trifluoroacetic Acid (SCHEMBL352350)	0.43	2/20
Glesatinib (SCHEMBL106319)	1.00	1/20
Azd-1480 (SCHEMBL219103)	1.00	1/20
Azd-1480 (SCHEMBL220400)	1.00	1/20
SCHEMBL275751	1.00	1/20

Clinical trials — most relevant to TNK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients	PHASE2	RECRUITING
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer	PHASE1/PHASE2	RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor	PHASE1	COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Brain as a Therapeutic and Research Target in Trigeminal Neuropathic Pain	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore	nan	COMPLETED
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC	nan	UNKNOWN
Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TNK1 binder may also engage these)

Protein	Name	Similarity
Q99ML2	—	1.000	Q99ML2 →
Q80XI6	—	0.992	Q80XI6 →
Q66HA1	—	0.991	Q66HA1 →
Q9BRR9	—	0.991	Q9BRR9 →
Q8WWN8	—	0.989	Q8WWN8 →
MAP3K11	Mitogen-activated protein kinase kinase kinase 11	0.988	landscape →
Q8BYG9	—	0.988	Q8BYG9 →
CDC42BPG	Serine/threonine-protein kinase MRCK gamma	0.987	landscape →
P0C0K6	—	0.987	P0C0K6 →
P54777	—	0.987	P54777 →
Q63474	—	0.986	Q63474 →
JAK3	Tyrosine-protein kinase JAK3	0.985	landscape →
P0C0K7	—	0.985	P0C0K7 →
P51840	—	0.985	P51840 →
MATK	Megakaryocyte-associated tyrosine-protein kinase	0.985	landscape →
Q03146	—	0.985	Q03146 →
MAP3K10	Mitogen-activated protein kinase kinase kinase 10	0.984	landscape →
D3ZG83	—	0.984	D3ZG83 →
Q66L42	—	0.984	Q66L42 →
Q5JZY3	—	0.983	Q5JZY3 →
Q9R117	—	0.983	Q9R117 →
Q8R5G7	—	0.983	Q8R5G7 →
Q8K330	—	0.983	Q8K330 →
DDR1	Epithelial discoidin domain-containing receptor 1	0.983	landscape →
O75064	—	0.983	O75064 →
Q16671	—	0.983	Q16671 →
Q96P48	—	0.982	Q96P48 →
Q9R011	—	0.982	Q9R011 →
TYK2	Non-receptor tyrosine-protein kinase TYK2	0.982	landscape →
P70218	—	0.982	P70218 →